Opposing Roles for MEK/ERK in Differentiation & Leukemia
MEK/ERK 在分化中的相反作用
基本信息
- 批准号:7496745
- 负责人:
- 金额:$ 3.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Promyelocytic LeukemiaAdoptive TransferBone MarrowBone Marrow CellsCD34 geneCell LineCell LineageCell SurvivalChemicalsConditionDefectDevelopmentDifferentiation TherapyEnzymesExhibitsFosteringGenerationsGrowthHematopoieticHumanIn VitroLeadMEK inhibitionMEKsMediatingModelingMusMyelogenousMyeloid CellsMyeloid LeukemiaMyelopoiesisOncogene ProteinsPathway interactionsPlayResearch PersonnelRoleSignal PathwaySignal Transduction PathwaySmall Interfering RNAStem cellsSystemTestingTetracyclineTetracyclinesTransgenic MiceTransgenic Modelcell growthcytokinehuman MAP2K1 proteinin vivoleukemialeukemogenesismouse modelnovelprogenitorprogramsretinoic acid receptor alpha
项目摘要
Myeloid leukemias are characterized by aberrant blockade of differentiation due to expression of leukemic
oncoproteins such as PML/RAR-alpha. Elucidation of the mechanisms responsible for normal myeloid
differentiation will further our understanding of differentiation blockades in leukemias, and foster the
development of novel differentiation therapies. Thus, our long-term objective is to define the intracellular
signaling pathways that lead to myeloid differentiation, and the role these pathways play in leukemogenesis.
In preliminary studies we have observed rapid and prolonged activation of the MEK/ERK signal
transduction pathway during myeloid differentiation. Furthermore, MEK/ERK activation was required for
differentiation in myeloid cell lines. This contrasts with known roles for MEK/ERK activation in proliferation
and survival, and constitutive MEK/ERK hyperactivation in myeloid leukemias. Together, these studies
suggest a dichotomy of roles for MEK/ERK activation: promoting differentiation under normal conditions,
and transformation under conditions where differentiation is blocked. Therefore, we hypothesize that
prolonged activation of the MEK/ERK pathway is critically important for cytokine-induced myeloid
differentiation. We further hypothesize that activation of the MEK/ERK pathway cooperates with
differentiation-inhibiting leukemic oncoproteins to promote leukemogenesis. To test this hypothesis, we will:
1) elucidate the importance of MEK/ERK activation during cytokine-induced myeloid differentiation of
myeloid cell lines and primary cultures of normal murine myeloid progenitors; 2) determine the functional
consequences of MEK/ERK activation during cytokine-induced myeloid differentiation; 3) examine whether
MEK/ERK activation promotes myeloid differentiation in vivo through the generation of transgenic mice that
inducibly express constitutively active MEK enzyme in myeloid lineage cells; and 4) determine whether
MEK/ERK activation cooperates with expression of PML/RAR-alpha to promote myeloid leukemogenesis.
髓性白血病的特征在于由于白血病细胞的表达而导致的分化的异常阻断。
癌蛋白如PML/RAR-α。阐明正常髓系细胞的机制
分化将进一步加深我们对白血病分化阻滞的理解,
开发新的分化疗法。因此,我们的长期目标是确定细胞内
导致骨髓分化的信号通路,以及这些通路在白血病发生中的作用。
在初步研究中,我们观察到MEK/ERK信号的快速和长期激活,
在骨髓分化过程中的转导途径。此外,MEK/ERK激活是必需的,
骨髓细胞系的分化。这与MEK/ERK活化在增殖中的已知作用形成对比
和生存,以及髓系白血病中的组成性MEK/ERK过度活化。这些研究一起
提示MEK/ERK活化作用的二分法:在正常条件下促进分化,
以及在分化被阻断的条件下转化。因此,我们假设
MEK/ERK通路的延长激活对于精氨酸诱导的髓样白血病至关重要。
分化我们进一步假设MEK/ERK通路的激活与
分化抑制白血病癌蛋白促进白血病发生。为了验证这个假设,我们将:
1)阐明MEK/ERK活化在苦参碱诱导的骨髓分化过程中的重要性。
正常鼠骨髓祖细胞的骨髓细胞系和原代培养物; 2)确定功能性骨髓祖细胞的功能,
3)检测在丝氨酸诱导的髓样分化过程中MEK/ERK活化的结果;
MEK/ERK激活通过产生转基因小鼠促进体内髓样分化,
在髓系细胞中诱导表达组成型活性MEK酶;和4)确定是否
MEK/ERK活化与PML/RAR-α表达协同促进髓系白血病发生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel E Johnson其他文献
A Simulation Suture Compared With a Clinical Suture for Training on Laparoscopic Simulators: Objective Measurements Indicate Acceptable Physical Characteristics.
用于腹腔镜模拟器训练的模拟缝合线与临床缝合线的比较:客观测量表明可接受的物理特征。
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Yazan Aljamal;Daniel E Johnson;Todd J Summerson;Thomas E. Belda;A. Thoreson;D. Farley - 通讯作者:
D. Farley
Daniel E Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel E Johnson', 18)}}的其他基金
Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma
Procaspase-8 突变对口腔鳞状细胞癌的影响
- 批准号:
9198543 - 财政年份:2016
- 资助金额:
$ 3.87万 - 项目类别:
EXERCISE REHABILITATION FOR THE OLDER CANCER PATIENT
老年癌症患者的运动康复
- 批准号:
7377810 - 财政年份:2006
- 资助金额:
$ 3.87万 - 项目类别:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
MEK/ERK 在分化中的相反作用
- 批准号:
7414012 - 财政年份:2005
- 资助金额:
$ 3.87万 - 项目类别:
EXERCISE REHABILITATION FOR THE OLDER CANCER PATIENT
老年癌症患者的运动康复
- 批准号:
7200590 - 财政年份:2005
- 资助金额:
$ 3.87万 - 项目类别:
Opposing Roles for MEK/ERK in Differentiation & Leukemia
MEK/ERK 在分化中的相反作用
- 批准号:
7614467 - 财政年份:2005
- 资助金额:
$ 3.87万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 3.87万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 3.87万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 3.87万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 3.87万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 3.87万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 3.87万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 3.87万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 3.87万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 3.87万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 3.87万 - 项目类别: